Acceleron Pharma (XLRN) PT Lowered to $46 at RBC Capital
Tweet
Share
E-mailGet Alerts XLRN Hot Sheet
Price: $178.75 --0%
Rating Summary:
11 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
11 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
RBC Capital analyst Kennen MacKay lowered the price target on Acceleron Pharma (NASDAQ: XLRN) to $46.00 (from $47.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
- Bally's Corp (BALY) PT Lowered to $10; Truist Securities: 'Mixed results amidst a "going concern"'
- Avita Medical Ltd. (RCEL) PT Raised to $14 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
